| Literature DB >> 21532719 |
Andre Pascal Kengne1, Eugene Sobngwi, Leopold Fezeu, Paschal Kum Awah, Sylvestre Dongmo, Jean-Claude Mbanya.
Abstract
BACKGROUND: This article describes the setting-up process for nurse-led pilot clinics for the management of four chronic diseases: asthma, type 2 diabetes mellitus, epilepsy and hypertension at the primary health care level in urban and rural Cameroon.Entities:
Keywords: Cameroon ; asthma ; chronic diseases ; diabetes ; epilepsy ; hypertension ; nurse-led clinics ; primary health care ; sub-Saharan Africa
Year: 2009 PMID: 21532719 PMCID: PMC2984281
Source DB: PubMed Journal: Pan Afr Med J
Figure 1:
Diagrammatic representation of the patients' flow in clinics
Patients registered in clinics at the first and second year evaluations and percentage change
| Hypertension | 115 | 120 | 4.3 (0.6–8) | 159 | 234 | 47.2 (39.4–55) |
| Diabetes | 38 | 180 | 373.7 (266.9–480.5) | 28 | 38 | 35.7 (18–53.4) |
| Asthma | 31 | 31 | 0 | 32 | 87 | 171.9 (133.4–210.4) |
| Epilepsy | 11 | 11 | 0 | 135 | 224 | 65.9 (65.9–73.9) |
| 195 | 342 | 75.4 (69.4–81.4) | 354 | 583 | 64.7 (59.7–69.7) | |
95% CI, 95% confidence interval
Treatments received by patients at the last clinic evaluation in the two rural and three urban clinics
| Aminophilline | 58.3% | 100% | - | - |
| Salbutamol | 41.7% | 0% | - | - |
| Prednisolone | 0% | 0% | - | - |
| Phenobarbital | 77.6% | 92.2% | - | - |
| Phenitoin | 19% | 2.6% | - | - |
| Carbamazepine | 0% | 1.3% | - | - |
| Lifestyle modifications | 3.4% | 3.9% | - | - |
| Lifestyle modifications | 7.1% | 0% | 12.5% | 9.5% |
| Glibenclamide | 71.4% | 33.3% | 70.8% | 23.8% |
| Gliclazide | 0% | 0% | 2.1% | 19.0% |
| Metformine | 7.1% | 33.3% | 0% | 4.8% |
| Metformine + Glibenclamide | 14.4% | 33.3% | 2.1% | 14.3% |
| Others | 0% | 0% | 12.9% | 28.6% |
| Lifestyle modifications | 0% | 0% | 0% | 9.1% |
| Glibenclamide | 75.0% | 100% | 80.8% | 36.4% |
| Gliclazide | 0% | 0% | 0% | 18.2% |
| Metformine | 25.0% | 0% | 0% | 4.5% |
| Metformine + Glibenclamide | 0% | 0% | 2.1% | 18.2% |
| Others | 0% | 0% | 17.1% | 13.6% |
| Lifestyle modifications | 0% | 0% | 8.5% | 4.5% |
| Hydrochlorothiazide (HCT) | 33.3% | 75% | 42.5% | 13.6% |
| Propranolol | 16.7% | 25% | 0% | 0% |
| Nifedipine | 16.7% | 0% | 12.8% | 13.6% |
| Methyldopa | 0% | 0% | 6.4% | 4.5% |
| Reserpine + Chlotalidone | 0% | 0% | 0% | 18.2% |
| Captopril | 0% | 0% | 6.4% | 13.6% |
| HCT + Propranolol | 0% | 0% | 0% | 4.5% |
| HCT + Nifedipine | 33.3% | 0% | 17% | 13.6% |
| HCT + Methyldopa | 0% | 0% | 6.4% | 4.5% |
| Others | 0% | 0% | 0% | 27.5% |
| Lifestyle modifications | 12.2% | 8.7% | - | 22.4% |
| HCT | 30.6% | 65.2% | - | 22.4% |
| Propranolol | 3.1% | 1.4% | - | 8.7% |
| Nifedipine | 13.7% | 10.1% | - | 6.2% |
| Methyldopa | 1.0% | 4.3% | - | 4.1% |
| Reserpine + Chlotalidone | 1.0% | 0% | - | 10.2% |
| HCT + Captopril | 0% | 0% | - | 2.0% |
| HCT + Propranolol | 7.1% | 0% | - | 0% |
| HCT + Nifedipine | 20.4% | 5.8% | - | 10.2% |
| HCT + Methyldopa | 11.2% | 4.3% | - | 4.1% |
| Others | 0% | 0% | - | 9.7% |
Urban 1&2: 2 urban clinics started in the 1 st year; Urban 3: urban clinic started in the second year of the program for diabetic patients only. Urban 1 & 2 are collapsed to account for the significant two-ways movement of patients between the two clinics.